Skip to main content

Market Research Outlook

Market Research Report

Market Research Report

India Ruxolitinib Market Entry Brief

Ruxolitinib, sold in India as Jakavi, loses Indian patent protection on 12 December 2026. This market entry brief tells a generic entrant what it needs to know before that date: the patent and litigation position, the Indian companies already lined up, the regulatory route, how prices moved at recent Indian openings, and a launch checklist.

 

Format Market entry brief (PDF)
Molecule Ruxolitinib (JAK inhibitor)
Indian patent expiry 12 December 2026 (IN 269841)
Price control Not in NLEM 2022
Published 17 November 2026, free update after first launches

 

What the brief answers

  • Exactly when the Indian patent ends, who owns it and what litigation is still live.
  • Which Indian companies were restrained in 2026 for moving early, and what that tells you about day one competition.
  • The regulatory route for a generic in India now that the drug is more than four years past its first approval.
  • What happened to price at five recent Indian openings, from palbociclib to semaglutide, and what to expect for ruxolitinib.
  • Who prescribes and buys, and an eight point launch checklist.

Key findings

  • Indian Patent IN 269841 expires on 12 December 2026.
  • Shilpa Medicare, Aurore Life Sciences and Melody Healthcare were each restrained by the Delhi High Court in 2026 before expiry.
  • Ruxolitinib is not under price control, so launch price is set by competition.
  • When palbociclib opened in 2023, the monthly cost fell from over Rs 80,000 to about Rs 3,800.

Why a brief, not a full report

A full market report sizes a whole market. A market entry brief answers one decision: should we launch this molecule in India, and how. It is built for business development, portfolio and launch teams who need a clear answer before a date.

Related: India Drug Patent Expiry Calendar | India Drug Market Entry Tracker | CDSCO Decoded

1. Summary
2. Patent position
3. Who is lined up
4. Regulatory route
5. Price and price control
6. Who prescribes and buys
7. Entry checklist
8. What we will update

Frequently Asked Questions

1. When does the ruxolitinib patent expire in India?

Ans: Indian Patent IN 269841 expires on 12 December 2026.

2. Which Indian companies are preparing ruxolitinib generics?

Ans: Shilpa Medicare, Aurore Life Sciences and Melody Healthcare were restrained by the Delhi High Court in 2026 for moving before expiry. Others may be preparing without having been sued.

3. Is ruxolitinib under price control in India?

Ans: No. It is not in the National List of Essential Medicines 2022, so there is no ceiling price.

4. What is included in the brief?

Ans: Patent and litigation position, Indian companies lined up, regulatory route, price benchmarks from recent Indian openings, buyers and an eight point launch checklist, with a free update after the first launches.
$750 One flat licence for your whole team